Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority of 4-days-per-week vs 7-days-per-week ART in virologically suppressed HIV-1 infection
2017-000040-17Phase 3Completed
- Sponsor
- Inserm-ANRS
- Start
- Jul 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenofovir disoproxil fumarate, emtricitabine, abacavir, lamivudine, lopinavir and 6 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Inserm-ANRS. Primary endpoint: Therapeutic success at week 48. Started Jul 2017; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabineabacavirlamivudinelopinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-000040-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000040-17.